+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human prostate tissue lysate, Primary antibody: P06627(GPR149 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P06627(GPR149 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

GPR149 (G protein-coupled receptor 149) is an orphan class A G protein-coupled receptor (GPCR) with poorly understood physiological functions and endogenous ligands. It is evolutionarily conserved and highly expressed in the central nervous system, particularly in regions like the hypothalamus, suggesting potential roles in neuroendocrine regulation or metabolic processes. Structural studies reveal a large N-terminal extracellular domain, a feature uncommon in class A GPCRs, which may participate in ligand binding or receptor dimerization. GPR149 exhibits constitutive activity in vitro, activating Gαs or Gαi/o signaling pathways depending on cellular context, but its in vivo signaling mechanisms remain unclear.

Antibodies targeting GPR149 are critical tools for investigating its expression patterns, subcellular localization, and interactions. They enable applications such as immunohistochemistry, Western blotting, and flow cytometry in both human and rodent models. Commercial GPR149 antibodies are typically raised against peptide sequences from the receptor’s extracellular or intracellular loops. However, specificity challenges persist due to homology with other GPCRs and lack of validated knockout controls. Recent research links GPR149 to metabolic disorders, reproductive functions, and cancer progression, driving demand for validated antibodies to explore its therapeutic potential. Robust antibody validation using CRISPR/Cas9-edited cell lines remains essential to minimize off-target artifacts in experimental studies.